TOP - May 2016, Vol 9, No 2
Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study. Read More ›
In the May issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium on the association between prophylactic gabapentin, weight loss, and narcotic dependency in patients with oropharyngeal cancer undergoing radiation therapy. Read More ›
- FDA Approves First and Only Blood-Based Colorectal Cancer Screening Test
- Imbruvica Now FDA Approved for First-Line Treatment of Patients with CLL
- Gazyva Approved for the Treatment of Relapsed or Refractory Follicular Lymphoma
- Ibrance Receives an Expanded Indication in Breast Cancer
- Kyprolis Receives New Indication for Relapsed or Refractory Multiple Myeloma
- FDA Grants Priority Review for Venetoclax as a Potential New Treatment for CLL
This therapy is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD) who develop renal or pulmonary dysfunction after undergoing hematopoietic SCT. Read More ›
By Wayne Kuznar
San Antonio, TX—A pilot study found that 70% of patient participants believed that text messages served as a reminder to take their endocrine therapy and wanted to continue receiving them. Read More ›
Atlanta, GA—Pharmacists involved in this program followed discharged patients and helped to decrease the number of readmissions in this population. Read More ›
Page 2 of 2
- 1
- 2